Thus, most clinicians recommend HER2-targeted therapies for these small tumors because HER2+ BC has an increased recurrence risk and due to the generally low toxicity of anti-HER2 agents, such as trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.